In vitro NASH Contract Research Services by CN Bio by CN Bio

Why does CN Bio offer In Vitro NASH Contract Research Services?

Despite a desperate need for NAFLD/ NASH therapeutics, we continue to observe late-stage candidate failures within the clinic. In part, this is due to the inability of preclinical models to adequately predict human responses. CN Bio’s In Vitro NASH Contract Research Service program is designed to help circumvent this issue, enabling better informed decisions about lead candidate safety and efficacy ahead of the clinic.

Which in vitro NAFLD/ NASH model does CN Bio use?

In just a few weeks and at a lower cost than animal studies, CN Bio can provide you with human translatable data generated using one of the most advanced NAFLD/ NASH in vitro models available. 
CN Bio’s disease model utilises their proprietary liver-on-a-chip technology which enables the longer-term in vitro culture (>1 month) of primary human liver cells on 3D scaffolds. The model recapitulates the functionality and microarchitecture of the human liver and when treated with Hep-Fat Media, transforms into a NASH phenotype that captures the following key aspects of the human disease: 

• intracellular fat accumulation/ hepatic steatosis
• inflammation 
• fibrosis 

Disease progression, as well as the health of liver cell types, is monitored against a range of different target pathways using a range of -omics, microscopy and biomarker assays. 

What types of screens does CN Bio offer?

This this complex, human relevant NAFLD/ NASH 3D in vitro model can be used for: 

• novel target identification
• drug efficacy and toxicology screening
• unlocking drug or disease mechanism of action 
• exploring donor to donor variability 
• investigating human drug dosing schedules 

Why should I add another pre-clinical test into our workflow?

Human relevant data generated using CN Bio’s model can be used to support (or call into question) the conclusions of internal preclinical studies, thus helping to prioritise lead candidates, fail flawed candidates, identify target clinical trial cohorts or optimise dosing regimens with greater confidence.

What are the benefits?

CN Bio’s in vitro NAFLD/ NASH model provides:

• rapid, low-cost data generation versus animal studies
• characterization of candidate responses against a range of physiologically relevant target pathways and liver cell types 
• human relevant efficacy data that better translates into clinical studies 
• more informed decisions regarding pre-clinical candidate prioritisation
• insights that influence the planning and optimisation of clinical trial design